Company Announcements

Correction: PDMR Shareholding

Source: RNS
RNS Number : 3010S
Clinigen Group plc
07 July 2020
 

7 July 2020

  

Correction: PDMR Shareholding

 

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, provides an amendment to the PDMR Shareholding announcement, released on 5 June 2020, as follows:

Section 4d of the announcement (price per share), and Section 4e (price) have been corrected to 886.5p. All other details remain the same.

The full amended text is shown below.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

John Hartup

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

213800OBIKGI2JYYS227

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Sale of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

886.5p per share

5,000 shares

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

5,000 shares

886.5p

£44,325

f)

Date of the transaction

5 June 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

Contact details

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Chief Executive Officer

Nick Keher, Chief Financial Officer

Matt Parrish, Head of Investor Relations

 

 

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

 

 

 

RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

 

 

 

Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Phillip Marriage

Email: clinigen@instinctif.com

 

Notes to Editors

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

 

For more information on Clinigen, please visit www.clinigengroup.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDZGGNDNKGGZM